Implicit Appoints Helen Roberts to Lead Business Development

BRISBANE, Australia, Dec. 3 /PRNewswire/ -- Implicit Bioscience has
appointed Helen Roberts as Director of Business Development. Helen brings to
Implicit over 18 years experience in the biotechnology and pharmaceutical
sector in a variety of senior commercial roles. Her responsibilities have
encompassed corporate and business development, leadership of sales, marketing
and product development teams, strategic planning and public affairs.
Most recently she served as Director, Clinical and Commercial Programs at
Brisbane-based Agenix where she was responsible for strategic clinical and
regulatory oversight, business development and commercialization planning for
their in vivo clot-imaging program.
Prior to that she worked with a number of top tier firms including Merck,
Bayer and American Cyanamid (now Wyeth) in roles of increasing scope and with
responsibility for flagship brands, both in Australia and overseas. Helen
graduated with a Bachelor of Applied Science in 1984 and earned her MBA from
University of Technology, Sydney in 1995.
About Implicit Bioscience
Implicit Bioscience is a privately-funded development stage
biopharmaceutical company with operations in Brisbane, Australia and Seattle,
Washington. The company has major strengths in immunology, peptide chemistry
and drug development, and is focused on the identification and development of
new therapies for infectious disease. Its current activities are focused on
the development of the immunomodulator oglufanide disodium in hepatitis C and
for biodefense applications.
SOURCE Implicit Bioscience

Dick Haiduck, Chief Business Officer of Implicit Bioscience, +1-650-851-3133,
dick.haiduck@implicitbiosicence.com; or Garry Redlich, CEO of Implicit
Bioscience Pty Ltd, +61 (0) 417 728 583, garry.redlich@implicitbioscience.com